Patents Assigned to Yissum Research Development Co.
-
Publication number: 20180258252Abstract: A process is provided for converting discarded rubber, e.g., rubber crumb, into absorbent material. The process comprises extruding a mixture of discarded rubber and oxidizer(s) under progressively increasing temperature to reach a temperature above 250° C. The extrudate may undergo a secondary oxidation. The partially devulcanized granular rubber formed is useful as absorbent material for hydrocarbons, e.g., in remediation of contaminated soil and oil spills.Type: ApplicationFiled: March 6, 2018Publication date: September 13, 2018Applicant: YISSUM RESEARCH DEVELOPMENT CO OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Yoel Sasson, Uri Stoin, Michael Kopylov, Vadim Goldshtein
-
Publication number: 20130203694Abstract: Rel proteins as a novel therapeutic agent for treating bacterial threats. More specifically, a novel class of compounds of Formula (I) as disclosed herein which possess anti-bacterial activity and which inhibit RelA, RelSeq or RelSpo synthetic activity or bacterial spore formation. Also, pharmaceutical compositions of such compounds and a method of combating bacteria, or treating bacterial infections, by administering to a subject in need thereof such compounds or pharmaceutical compositions.Type: ApplicationFiled: August 3, 2011Publication date: August 8, 2013Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Ezequiel Wexselblatt, Joshua Katzhendler, Gad Glaser, Sigal Ben Yehuda, Roee Vidavski, Hafiz Mawasi, Ilana Kaspy, Yaara Oppenheimer-Shaanan
-
Patent number: 8471969Abstract: The present invention provides and optical display device and a method for use in displaying an image. The optical display device comprises An optical display device comprising: at least one region of nanostructures operable as an optically active media, such that said nanostructures are responsive to input electromagnetic radiation to emit output electromagnetic radiation, and an arrangement of electrodes being configured and operable to be selectively addressable to create an external electric field to said at least one region of nanostructures, said region of nanostructures and said arrangement of electrodes defining together a pixel arrangement of said display device; said external electric field affecting said at least one region of nanostructures to selectively modulate emission of said output electromagnetic radiation, said output electromagnetic radiation being an output of at least one pixel element of the display device.Type: GrantFiled: February 23, 2010Date of Patent: June 25, 2013Assignees: Merck Patent GmbH, Yissum Research Development Co.Inventors: Uri Banin, Volker Hilarius, Assaf Aharoni, Hagai Arbell
-
Publication number: 20100292152Abstract: Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases.Type: ApplicationFiled: May 9, 2006Publication date: November 18, 2010Applicants: Yissum Research Development Co. of the Hebrew University of Jersalem, Medical Research Fund of Tel Aviv Sourasky Medical CenterInventors: Itshak Golan, Dan Caspi, Lora Melnik
-
Patent number: 7692664Abstract: In a method and system for matting a foreground object F having an opacity ? constrained by associating a characteristic with selected pixels in an image having a background B, weights are determined for all edges of neighboring pixels for the image and used to build a Laplacian matrix L. The equation ? is solved where ?=arg min ?T L? s.t.?i=si, ?i?S, S is the group of selected pixels, and si is the value indicated by the associated characteristic. The equation Ii=?iFi+(1??i)Bi is solved for F and B with additional smoothness assumptions on F and B; after which the foreground object F may be composited on a selected background B? that may be the original background B or may be a different background, thus allowing foreground features to be extracted from the original image and copied to a different background.Type: GrantFiled: July 6, 2009Date of Patent: April 6, 2010Assignee: Yissum Research Development Co.Inventors: Yair Weiss, Daniel Lischinski, Anat Levin
-
Publication number: 20100048721Abstract: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a pharmaceutical composition comprising the compounds for treating a psychiatric disorder. A method for treating a psychiatric disorder preferably a bipolar disorder and a method for inhibiting an enzyme having MIP synthase activity is provided.Type: ApplicationFiled: May 27, 2004Publication date: February 25, 2010Applicants: Yissum Research Development Co. of the Hebrew University of Jerusalem, Ben Gurion University of the Negev Research and Development AuthorityInventors: Meir BIALER, Boris YAGEN, Haim BELMAKER, Galila AGAM, Galit SHALTIEL
-
Publication number: 20090278859Abstract: In a method and system for matting a foreground object F having an opacity ? constrained by associating a characteristic with selected pixels in an image having a background B, weights are determined for all edges of neighboring pixels for the image and used to build a Laplacian matrix L. The equation ? is solved where ?=arg min ?T L? s.t.?i=si, ?i?S, S is the group of selected pixels, and si is the value indicated by the associated characteristic. The equation Ii=?iFi+(1??i)Bi is solved for F and B with additional smoothness assumptions on F and B; after which the foreground object F may be composited on a selected background B? that may be the original background B or may be a different background, thus allowing foreground features to be extracted from the original image and copied to a different background.Type: ApplicationFiled: July 6, 2009Publication date: November 12, 2009Applicant: Yissum Research Development Co.Inventors: Yair Weiss, Daniel Lischinski, Anat Levin
-
Publication number: 20090221478Abstract: Isolated polynucleotides encoding novel galectin-8 variants polypeptides are provided. Also provided are methods and kits using same for diagnosing prognosing and treating rheumatoid arthritis (RA) and other joint/chronic inflammatory diseases.Type: ApplicationFiled: May 9, 2006Publication date: September 3, 2009Applicants: Yissum Research Development Co. of the Hebrew University of Jersalem, Medical Research Fund of Tel Aviv Sourasky Medical CenterInventors: Itshak Golan, Dan Caspi, Lora Melnik
-
Publication number: 20090062197Abstract: SP1 and modified SP1 variant polypeptides capable of forming reversible molecular associations with substances, compositions-of-matter comprising same, and uses thereof are provided.Type: ApplicationFiled: July 9, 2006Publication date: March 5, 2009Applicants: Fulcrum SP Ltd., Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Amnon Wolf, Yenonathan Pouny, Ira Marton, Or Dgany, Arie Altman, Oded Shoseyov
-
Patent number: 7357944Abstract: Liposomal bupivacaine compositions are prepared using an ammonium sulfate gradient loading procedure, at a pH which prevents precipitation of the drug from the loading solution. Also described are liposome suspensions comprising ‘GMV’ (giant multivesicular) liposomes and methods for their preparation. The liposomal compositions are characterized by high drug-to-lipid ratios and provide long term analgesia.Type: GrantFiled: February 5, 2004Date of Patent: April 15, 2008Assignees: New York University, Yissum Research Development, CoInventors: Elijah M. Bolotin, Gilbert J. Grant, Yechezkel Barenholz, Herman Turndorf, Boris Piskoun
-
Publication number: 20080015251Abstract: A method for treating symptoms of a lipotoxicity-related phenomenon includes introducing into a patient a therapeutically effective synergistic amount of a phenomenon-inhibiting cocktail of a polyphenol (P), thiol antioxidant (To) and ascorbic acid (A) to reduce intracellular reactive oxygen species (ROS) and/or increase intracellular nitrite (NO), so that reduction of such phenomenon is at least 30% greater than the reduction of such phenomenon provided by separate administration of each of P, To and A.Type: ApplicationFiled: April 10, 2007Publication date: January 17, 2008Applicant: Yissum Research Development Co., of The Hebrew University of JerusalemInventors: Oren Tirosh, Zecharia Madar, Anna Aronis, Erez Ilan
-
Publication number: 20070165966Abstract: In a method and system for matting a foreground object F having an opacity ? constrained by associating a characteristic with selected pixels in an image having a background B, weights are determined for all edges of neighboring pixels for the image and used to build a Laplacian matrix L. The equation ? is solved where ?=arg min ?T L? s.t.?i=si, ?i ? S, S is the group of selected pixels, and si is the value indicated by the associated characteristic. The equation Ii=?iFi+(1??i)Bi is solved for F and B with additional smoothness assumptions on F and B; after which the foreground object F may be composited on a selected background B? that may be the original background B or may be a different background, thus allowing foreground features to be extracted from the original image and copied to a different background.Type: ApplicationFiled: July 17, 2006Publication date: July 19, 2007Applicant: Yissum Research Development Co.Inventors: Yair Weiss, Daniel Lischinski, Anat Levin
-
Patent number: 7214716Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)- type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: January 27, 2005Date of Patent: May 8, 2007Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Publication number: 20070043122Abstract: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a pharmaceutical composition comprising the compounds for treating a psychiatric disorder. A method for treating a psychiatric disorder preferably a bipolar disorder and a method for inhibiting an enzyme having MIP synthase activity is provided.Type: ApplicationFiled: May 27, 2004Publication date: February 22, 2007Applicants: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM, BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITYInventors: Meir Bialer, Boris Yagen, Haim Belmaker, Galila Agam, Galit Shaltiel
-
Publication number: 20060215934Abstract: A computer-implemented method and system determines camera movement of a new frame relative to a sequence of frames of images containing at least one dynamic object and for which relative camera movement is assumed. From changes in color values of sets of pixels in different frames of the sequence for which respective locations of all pixels in each set are adjusted so as to neutralize the effect of camera movement between the respective frames in the sequence containing the pixels, corresponding color values of the pixels in the new frame are predicted and used to determine camera movement as a relative movement of the new frame and the predicted frame. An embodiment of the invention maintains an aligned space-time volume of frames for which camera movement is neutralized and adds each new frame to the aligned space-time volume after neutralizing camera movement in the new frame.Type: ApplicationFiled: March 20, 2006Publication date: September 28, 2006Applicants: Yissum Research Development Co of the Hebrew University of Jerusalem Israeli Co, HumanEyes Technologies Ltd. Israeli CoInventors: Shmuel Peleg, Alexander Rav-Acha, Yael Pritch
-
Publication number: 20060183309Abstract: A method for forming a micro- or nano-pattern of a material on a substrate is presented. The method utilizes a buffer layer assisted laser patterning (BLALP). A layered structure is formed on the substrate, this layered structure being in the form of spaced-apart regions of the substrate defined by the pattern to be formed, each region including a weakly physisorbed buffer layer and a layer of the material to be patterned on top of the buffer layer. A thermal process is then applied to the layered structure to remove the remaining buffer layer in said regions, and thus form a stable pattern of said material on the substrate resulting from the buffer layer assisted laser patterning. The method may utilize either positive or negative lithography. The patterning may be implemented using irradiation with a single uniform laser pulse via a standard mask used for optical lithography.Type: ApplicationFiled: March 4, 2004Publication date: August 17, 2006Applicant: Yissum Research Development Co, of the Hebrew University of JerusalemInventors: Micha Asscher, Gabriel Kerner
-
Patent number: 6949565Abstract: Novel isoquinoline derivatives which are useful as inhibitors of protein kinases for experimental, medical, and drug design purposes are disclosed. Preferred compounds which are specific inhibitors of protein kinase B are also disclosed. Furthermore, pharmaceutical compositions comprising these protein kinase inhibitors, and methods of using such compositions for treatment and diagnosis of cancers, diabetes, cardiovascular pathologies, hemorrhagic shock, obesity, inflammatory diseases, diseases of the central nervous system, and autoimmune diseases, are also disclosed.Type: GrantFiled: May 30, 2001Date of Patent: September 27, 2005Assignees: Develogen Israel Ltd., Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Nurit Livnah, Alexander Levitzki, Hadas Reuveni
-
Publication number: 20050165118Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: ApplicationFiled: January 27, 2005Publication date: July 28, 2005Applicant: YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Patent number: 6903137Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: April 26, 2002Date of Patent: June 7, 2005Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon
-
Patent number: 6864291Abstract: The invention provides novel pharmaceutical compositions comprising as the active ingredient 4-phenyl pinene derivatives which are specific for the peripheral cannabinoid receptors. In particular, the compounds of the invention binds efficiently to CB2 but do not bind to CB1. The compounds show no activity in behavioral tests in mice which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the central nervous system mediated by CB1 but reduce blood pressure, block intestinal motility, and elicit anti-inflammatory and peripheral analgetic activity. The invention also relates to methods of treating, preventing, or managing hypertension, inflammation, pain, gastrointestinal diseases, autoimmune diseases, and tumors with the compounds of the invention.Type: GrantFiled: October 30, 2000Date of Patent: March 8, 2005Assignee: Yissum Research Development Co. of the Hebrew University of JerusalemInventors: Ester Fride, Aviva Breuer, Lumir Hanus, Susanna Tchilibon, Michal Horowitz, Raphael Mechoulam, Aaron Garzon